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Introduction: Prior studies have established altered microbiota and immunologic reactivity to enteric commensal
organisms in inflammatory bowel disease (IBD). Since intestinal inflammation is present in a subset of patients with
both pediatric and adult spondyloarthritis (SpA), we hypothesized that SpA patients may also have altered
microbiota and immune responsiveness to enteric organisms.
Methods: Stool and blood specimens were collected from children with enthesitis-related arthritis (ERA) and
non-inflammatory controls. DNA purified from stool was subject to PCR amplification and sequencing of the
variable IV region from the 16S rDNA gene. IgA and IgG Enzyme-linked Immunosorbent Assays (ELISAs) were
performed on select species of bacteria in most subjects.
Results: Twenty-five children with ERA and 13 controls were included. The ERA patients had less Faecalibacterium
prausnitzii (3.8% versus 10%, P = 0.008) and lachnospiraceae family (12 versus 7.0%, P = 0.020), a statistically
significant increase in bifidobacterium (1.8% versus 0%, P = 0.032) and a non-statistically significant increase in
Bacteroides (21% versus 11%, P = 0.150). Akkermansia muciniphila was abundant (>2%) in 7/27 ERA patients but
none of the controls (P = 0.072.) Cluster analysis revealed two clusters of ERA patients: Cluster one (n = 8) was
characterized by high levels of Bacteroides genus, while a second (n = 15) cluster had similar levels as the controls.
Seven of 17 (41%) of the ERA subjects in Cluster 2 compared to 0/8 of the subjects in Cluster 1 had abundant
Akkermansia muciniphila (P = 0.057). Serum IgA and IgG antibody levels against F. prausnitzii and B. fragilis were
similar between patients and controls, whereas the two groups showed divergent responses when the fecal relative
abundances of F. prausnitzii and Bacteroides were compared individually against IgA antibody levels recognizing
F. prausnitzii and B. fragilis, respectively.
Conclusion: The abundance of F. prausnitzii in the stool among patients with ERA is reduced compared to controls,
and Bacteroides and A. muciniphila are identified as associative agents in subsets of ERA patients. Differences in the
humoral responses to these bacteria may contribute to disease.Introduction
Spondyloarthritis (SpA) affects up to 1% of the population
in the United States [1]. Recent genetic advances have
shed some light on pathogenesis and have shown impor-
tant overlap with inflammatory bowel disease (IBD) [2,3];
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stated.components. Given the association between gut inflam-
mation and SpA [4], one potential environmental trigger
that has long attracted attention is the microbiota; indeed,
the disease is abrogated in an HLA-B27 transgenic rodent
model of colitis and spondylitis when the animals are
raised in a germ-free environment [5].
Advances in technology, collectively known as next-
generation sequencing, have dramatically lowered the
costs of sequencing and thus permitted collections of vast
amounts of data, as many as one billion short sequences,
in one run [6]. One of the applications has been the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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individuals. Studies have shown altered microbiota in a var-
iety of inflammatory conditions, including IBD, rheumatoid
arthritis (RA), type I diabetes, and celiac disease [7]. Using
a variety of molecular approaches, Stebbings et al. [8]
demonstrated possible decreases in the Bacteroides-Provo-
tella and Clostridium leptum groups, with an increase in
Bifidobacterium among ankylosing spondylitis (AS) pa-
tients compared to controls, although the overall dif-
ferences were not statistically significant [8]. As this study
did not use next generation sequencing technology, the
nature of the microbiota in SpA patients has yet to be fully
assessed.
Intestinal bacteria need not be present in abnormal
quantities to trigger arthritis; it is also possible that a
pathologic immune response to normal resident microbes
may result in disease. Fifty percent of patients with
Crohn’s disease (CD) express antibodies directed against
flagellins of the microbiota, with these antibodies associa-
ted with stricturing disease [9]. Flagellin antibodies have
also been identified in SpA patients, albeit at lower titers
[10]. It is unknown whether additional bacteria may be
targeted in SpA patients; even in CD, there is evidence of
seroreactivity to other antigens of the microbiota [11].
Additionally, Stebbings et al. [8] demonstrated decreased
IgA antisera to Bacteroides vulgatus among AS patients,
despite increased T cell proliferative responses to auto-
logous Bacteroides [8]; the same group subsequently de-
monstrated decreased production of the regulatory
cytokine IL-10 by peripheral blood mononuclear cells of
AS patients compared to controls [12]. Thus, altered im-
munologic reactivity to commensal organisms, possibly
including Bacteroides, may also play an important role in
SpA. Herein, sequencing of the 16S ribosomal DNA
(rDNA) of patients with enthesitis-related arthritis (ERA;
juvenile SpA) and controls was performed, followed by
assessment of antigenic reactivity against bacteria differen-
tially present in the patients versus the controls. We hy-
pothesized that ERA patients may have altered microbiota
affecting immune responsiveness to enteric microbiota.
Methods
Patients
This study was conducted at a single hospital, Children’s
of Alabama (CoA). SpA was defined according to the
International League of Associations for Rheumatology
criteria for juvenile idiopathic arthritis subtype, ERA
[13]. Controls came from the following sources: 1) chil-
dren referred to rheumatology clinic, but found to have
non-inflammatory causes of joint pain or irrelevant
laboratory values (for example, positive antinuclear anti-
body (ANA) in a well child [14]), and 2) children from the
community identified through advertisements or parental
affiliation with CoA. Subjects with recent (within 6 months)use of systemic antibiotic therapy were excluded. Clinical,
demographic, and laboratory data were obtained through
chart review and use of case report forms. Informed con-
sent was obtained from guardians as well as subjects age
14 years and older; assent was obtained from children ages
7 to 13 years. Institutional Review Board approval was ob-
tained from the University of Alabama at Birmingham.
Preparation and sequencing of 16S rDNA from fecal
material
Subjects collected the samples at home and immediately
placed the samples in a 50-ml container filled with Carey-
Blair media [15]. Samples were shipped overnight via com-
mercial carrier to our laboratory. Microbial genomic DNA
was isolated by standard methods using a kit from Zymo
Research (Irvine, CA, USA) as per the manufacturer’s
instructions. The purified DNA underwent PCR amplifica-
tion using primers designed to the conserved region flan-
king the variable IV region from the 16S rDNA gene, as
per Caporaso et al. [16]. Purification of the resulting PCR
product was performed with a Qiagen kit (Valencia, CA,
USA) as per the manufacturer’s instructions. A second
purification with Agencout AmPure beads (Danvers, MA,
USA) was performed to increase the quality of the DNA
amplicons. The PCR products were multiplexed and di-
luted for cluster generation using the cBot on a single read
v.3 flowcell for the HiSeq2000 (Illumina, San Diego, CA,
USA); a few samples were run on the MiSeq (Illumina,
San Diego, CA, USA), with the sequences truncated to
101 base pairs to match that of the HiSeq output. Fastq
conversion of the raw data files was performed following
demultiplexing. Quality control of the fastq files was per-
formed with the FASTX toolkit [17]. The remainder of the
steps was performed with the Quantitative Insight into
Microbial Ecology (QIIME) suite, version 1.7 [16]. Opera-
tional taxonomic units (OTUs) were picked with uclust
[18] at 99% similarity. Taxonomic assignments to OTUs
were performed with the Ribosomal Database Project clas-
sifier [19], which was trained with the May 2013 version of
the Greengenes 16S database [20]. Multiple sequence
alignment of OTUs was performed with PyNAST [21].
Within-sample (alpha) diversity measures were calculated
with Shannon and Phylogenetic Diversity [22], and beta-
diversity was calculated with Unifrac [23]. Principal coor-
dinates analysis (PCoA) was performed by QIIME to
visualize the dissimilarity matrix (beta-diversity) among all
the samples, such that samples that are more similar with
respect to their taxanomic distribution are closer together
in space than samples that are less similar. To assess the
statistical significance of the clusters observed from the
PCoA, the R package pvclust was used [24]. Pvclust per-
formed hierarchical clustering using the correlation dis-
tance matrix; to estimate stability of the resulting clusters,
it performed bootstrap analysis at 10,000 iterations, each





Age, years, median, range 13.0, 7.0 to 19.0 13.0, 5.8 to 18.0
Male:female, number 11:14 6:7
Body mass index,
median, range




2.4, 0 to 8.2 N/A






9, 3 to 56
Medications
None, number 7 (28%) 13 (100%)
Methotrexate alone, number 2 (8.0%)




DMARD, disease-modifying anti-rheumatic drug (methotrexate, leflunomide);
TNF, tumor necrosis factor; N/A, not applicable.
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placement.) The output yields the approximate unbiased
(AU) and the bootstrap probability (BP) values of each
cluster, with the former said to be less subject to bias as
per the original description [24].
ELISA
Serum samples obtained at approximately the time of the
collection of the stool specimens were centrifuged and
stored at −80°C until ready for use. ELISA was performed
to measure IgA or IgG reactivity in 96-well flat-bottom
Costar plates (Fisher, Rockville, MD, USA). In preliminary
studies, amounts of lyophilized bacteria antigen and
serum dilutions were optimized to identify parameters
that permitted reproducible results that differentiated
serum samples from negative controls. The optimized
amounts of bacterial lysate antigen were 50 ng for Bacte-
roides fragilis strain 086-5443-2-2 (kindly donated by
Cindy Sears), 250 ng for Akkermansia muciniphila (ATCC
# BAA-835), and 100 ng for Faecalibacterium prausnitzii
(ATCC # 27766). Plates were coated with the specified
amount of antigen in 50 μl of PBS for four hours at 37°C,
then were transferred to store at 4°C overnight. After
blocking with 5% milk, serum was added in duplicate at a
1:50 dilution for two hours at room temperature, followed
by the addition of anti-human IgG or IgA conjugated to
peroxidase (Sigma, St Louis, MO, USA) at a 1:10,000 di-
lution overnight at 4°C. Plates were developed with
para-nitrophenyl phosphate and scanned at the 490 nm
wavelength.
Statistical analysis
Comparisons of individual taxa were performed with the
Mann-Whitney U-test for two groups and the Kruskal-
Wallis test for three groups. Nominal data were evaluated
with the chi-squared test. Correlation analyses were per-
formed with the Spearman coefficient. Additionally, IgA
and IgG antibodies against B. fragilis and F. prausnitzii
were analyzed using a linear model with fecal presence of
Bacteriodes and F. prausnitzii, respectively, using diagno-
sis (patient or control) and the interaction of these two
terms as predictors. A two-sided t-test was used to test
each term for significance, which was set at 0.05. These
analyses were performed with SPSS, Version 17 (Chicago,
IL, USA) and R (version 3.0.2.)
Results
Patients
Clinical and demographic features of the study patients are
shown in Table 1. In total 25 children with ERA (11 female,
age (median, range) 13, 7 to 19 years) and 13 controls
(7 female, age 13, 5 to 17 years) were included in the
study. Two of the ERA subjects had IBD. Twenty-onepatients, but no controls, were on immunosuppressive
therapy.
Results of 16S sequencing analysis
High-quality sequence data were obtained from fecal
samples on all 38 children. Following the filtering step,
the sequencing depth ranged from 9,000 to 555,000,
with a sequence length of 101 base pairs. There were no
differences in within-subject (alpha) diversity measure-
ments between the groups (not shown). The taxonomic
distribution of the top 20 taxa is shown in Figure 1A. Of
these, the only two taxa with statistically significant
differences favoring the controls were the Faecalibacter-
ium genus (11% versus 5.2%, P = 0.005) and unspecified
genera of the Lachnospiraceae family (12% versus 7.0%,
P = 0.020). Among those favoring ERA, Bifidobacterium
showed a modest but statistically significant increase
(1.8% versus 0%, P = 0.032), and Bacteroides demon-
strated a larger but statistically non-significant increase
(21% versus 11%, P = 0.150). Analysis at the species level
revealed that 84% of the Faecalibacterium sequences
represented a single species: Faecalibacterium praus-
nitzii, which constituted 10% of the microbiota of con-
trol patients versus 3.8% in the ERA group (P = 0.008.) A
basic local alignment search tool (BLAST) search of the
OTU representing the majority of the unspecified Lach-
nospiraceae family members revealed two matches at
100% identified: Fusicatenibacter saccharivorans and
Clostridium clostridioforme. Thus, it is unclear which of
Figure 1 Decreased abundance of Faecalibacterium genus in enthesitis-related arthritis (ERA) patients compared to controls. (A) The
relative abundance of the top 20 taxa are shown. Although the taxa were evaluated at the genus level, some of the operational taxonomic units
(OTUs) were only identified at the family level or above. Negative values (left) indicate higher frequency in controls, and positive values (right)
indicate higher frequencies in patients. Statistically significant differences (Mann-Whitney U-test) are depicted in a darker gray color. (B) The
distribution of F. prausnitzii levels is shown.
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seven percent of the Bifidobacterium sequences repre-
sented B. adolescentis. The distribution of F. prausnitzii
levels in patients and controls is depicted in Figure 1B.
Additionally, A. muciniphila was present in very low
quantities in most patients, but was relatively abundant
(>2%) in 7/25 (28%) patients, but not in any of the 13
controls (P = 0.072, Fisher’s exact). There were no sig-
nificant associations between the body mass index of
the subjects and presence of any of these bacteria
(Additional file 1: Table S1.) Among subjects with ERA,
HLA-B27 status was not associated with significant dif-
ferences in the levels of these bacteria (Additional file 1:
Table S2).
Thus, at the genus and species level, our data demon-
strate some statistically significant differences between
patients and controls. Our next step was to assess whe-
ther patients and controls may have different overall
communities of enteric bacteria. This was evaluated with
PCoA (Figure 2A), which demonstrated that while most
of the patients clustered with the controls, a set of eight
ERA patients formed their own cluster. To confirm the
existence of this cluster, we performed bootstrap analysis
using pvclust, with the results showing an identical cluster
with an AU probability of 99% (Figure 2B.) Comparing the
eight ERA patients in cluster 1 with the remainder of the
ERA subjects, the former had significantly higher Bacte-
roides levels (32% versus 13%, P <0.001), with no differ-
ence in the F. prausnitzii content (4.7% versus 3.2%,
P = 0.897). The subgroup of ERA patients with eleva-
ted Bacteroides content appeared to be under-represented
among those patients with high levels (>2%) of Akkermansia,
which was found in 0/8 of cluster 1 compared to 7/17(41%) of cluster 2 (P = 0.057). Despite the predominance
of Bacteroides among the subjects in cluster 1, the
Shannon index was similar between the two clusters
(Figure 3A). However, cluster 1 demonstrated diminished
alpha diversity with the phylogenetic diversity metric (3B).
The two clusters otherwise appeared similar with respect
to most clinical and laboratory features, with the excep-
tion that cluster 1 was predominantly female and cluster 2
predominantly male (Table 2.)
Thus, there appear to be significant differences in the
populations of enteric bacteria between patients and con-
trols. In order to assess whether the alterations in the fre-
quencies of the bacterial genera could be associated with
changes in the immunoreactivity, we performed ELISA
against a Bacteroides species (B. fragilis) and F. prausnitzii
among the 31 subjects (22 patients and 9 controls) in
whom we had serum samples available, including both
with IBD. Overall, there were no significant differences in
IgA or IgG reactivity against any of the bacteria (Table 3),
although HLA-B27+ subjects had elevated antibody pro-
duction against both (Additional file 1: Table S2.) When
broken down by cluster, ERA subjects in cluster 1, cha-
racterized by increased bacteroides, also demonstrated in-
creased IgA and IgG reactivity against B. fragilis, the
latter statistically significant at P = 0.05 (Additional file 1:
Table S3). Interesting trends emerged when we evaluated
antibody production against a particular species as a func-
tion of the quantity of the associated bacteria. There was a
strong correlation (r = 0.511, P = 0.003) between Bacte-
roides content and IgG antibodies against B. fragilis
among the group as a whole. In contrast, while the overall
correlation between Bacteroides content and IgA anti-
bodies was weak (r = 0.300, P = 0.067), divergent trends
Figure 2 Spondyloarthritis (SpA) patients have two distinct clusters. In principal coordinates analysis (A) each subject is a separate dot; the
closer two subjects are in space, the more similar their sequence data. Enthesitis-related arthritis (ERA) subjects are shown in blue, controls in red.
The asterisks over eight of the subjects indicate subjects identified as well with the pvclust bootstrap analysis (B). The same eight subjects are
present in the identified cluster.
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demonstrated a similar positive correlation (r = 0.481,
P = 0.005), while an inverse although not statistically
significant correlation was seen in the control group
(r = −0.483, P = 0.187). Linear modeling of the slopes of the
two regression lines demonstrated a statistically significant
interaction between IgA levels against B. fragilis and diag-
nosis (P = 0.008), not present with IgG (P = 0.105). A si-
milar discordance was seen with F. prausnitzii (Figure 5),Figure 3 Alpha diversity metric comparing clusters 1 and 2. The Shan
probability of being able to predict the identity of a randomly drawn sequ
length of all branches of the phylogenetic tree of a given population [22].although in this case, patients demonstrated an inverse
correlation between IgA antibodies to F. prausnitzii and
F. prausnitzii content (r = −0.404, P = 0.062), with controls
demonstrating a strong positive correlation (r = 0.850,
P = 0.004); as with B. fragilis, the slopes of the two curves
were statistically significantly different (P = 0.039). Neither
group demonstrated a strong correlation in either direc-
tion between fecal F. prausnitzii content and IgG anti-
bodies to the same, although they trended in the samenon index is shown in A; this measures species evenness, or the
ence. The phylogenetic diversity is shown in B; this evaluates the
Table 2 Comparison of clinical and laboratory features of children in cluster 1 versus cluster 2
Feature Cluster 1 Cluster 2 P-value
Number 8 17 N/A
Age, years, median, range 13, 7 to 18 13, 7.5 to 19 0.932
Male:female, number 1:7 13:4 0.007
Body mass index, median, range 20, 16 to 33 23, 16 to 41 0.374
Disease duration, years, median, range 1.6, 0 to 6.5 3, 0 to 8.2 0.238
HLA-B27+, number 3/8, 38% 6/16, 38% 1.000
Known inflammatory bowel disease, number 1, 12% 1, 5.9% 1.000
Erythrocyte sedimentation rate, number: median, range 7: 10, 6 to 50 13: 9, 3 to 56 0.536
Medications, number
None 2, 25% 5, 29%
Methotrexate alone 0 2, 12%
Pentasa alone 0 1, 5.9%
Anti-TNF +/− conventional DMARD 6, 75% 9, 53%
DMARD, disease-modifying anti-rheumatic drug; TNF, tumor necrosis factor; N/A, not applicable.
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P = 0.615).
Discussion
The human intestine is colonized with an estimated 100
trillion bacteria, a process that begins shortly after birth
[25]. It is becoming increasingly clear that these bacteria
play important roles in immune function as well as in a
variety of autoimmune and inflammatory disorders [25].
One condition with important microbial contributions is
IBD, as evidenced by aberrant microbial content [26],
therapeutic response to antibiotics in CD [27], and ab-
normal innate and adaptive immunologic responses to
enteric bacteria [28]. There is also interest in the role of
the microbiota in SpA [29], with a previous study sho-
wing possible decreases in the Bacteroides-Provotella
and Clostridium leptum groups, with an increase in
Bifidobacterium among AS patients compared to con-
trols, although the overall differences were not statisti-
cally significant [8].
In this study, four candidate organisms are identified
as being potentially associated with ERA. Decreased
F. prausnitzii, was seen in the patients compared to con-




B. fragilis 0.11, 0.16,
0 to 0.21 0.094 to 0.343
F. prausnitzii 0.15, 0.18,
0.043 to 0.51 0.14 to 0.29
ERA, enthesitis-related arthritis. Values are median (min - max). o.d. = optical densitreported in patients with IBD [30-32], and may be of
particular significance in light of its reported anti-
inflammatory effects [33]. It may also be consistent with
the previous finding of decreases in the Clostridium
leptum group in AS patients [8], as both C. leptum and
F. prausnitzii are in the clostridiaceae family. F. praus-
nitzii is an important producer of butyrate [34], which
may have anti-inflammatory properties [35]; there was
no compensatory increase in other butyrate-producing
bacteria, such as the Eubacterium and Roseburia genera
(data not shown) [34,36]. These findings underscore
the pathogenic similarities between IBD and ERA, as
F. prausnitzii was not reduced in a study of newly diag-
nosed RA patients [37]. Additional evidence of microbial
similarities between IBD and ERA comes from the study
by Frank et al. [32], which showed not only decreased
F. prausnitzii in the IBD patients, but also decreases in
the Lachnospiraceae family. In particular, there may have
been a decrease in Clostridium clostridioforme, which
was one of the two potential organisms associated with
the dominant OTU in the Lachnospiraceae family sig-
nificantly under-represented in the ERA patients. That
these differences may result from genetic differences
between the populations, rather than from the diseaseacteria differentially present between patients and
IgG
-value ERA Control P-value
0.094 0.41, 0.43, 0.536
0.095 to 1.3 0.20 to 1.6
0.112 0.45, 0.46, 0.742
0.21 to 1.6 0.22 to 1.6
y.
Figure 4 Divergent relationships between B. fragilis IgA levels and fecal Bacteroides content, between patients and controls.
Enthesitis-related arthritis (ERA) subjects are depicted in blue (broken line); controls are red (solid line).
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NOD2 and ATG16L1 genotypes were associated with al-
tered microbial populations even with adjustment for
diagnosis of IBD [38]. This information was not available
for our patients.
A novel finding of this study is that both Bacteroides
species and Akkermansia muciniphila were found to be
associated with disease states in largely non-overlapping
subsets of ERA patients. These subsets were similar with
respect to most clinical and laboratory features, aside from
cluster 1 being predominantly female, and cluster 2 pre-
dominantly male. The potential relevance of this distinc-
tion awaits further exploration. B. fragilis is considered to
have regulatory effects through its polysaccharide A [39],
although the enterotoxigenic strain of B. fragilis has been
linked to IBD [40]. Additionally, in both a rat and a mouse
model of SpA abrogated by the germ-free state, addition
of a consortium of bacteria that includes bacteroides spe-
cies results in active disease, with B. vulgatus specifically
identified as a causative agent in the rat model [41,42].
Furthermore, as indicated above, abnormal humoral and
T cell responses to bacteroides has been reported in ASpatients [8,12]. The data reported herein indicated that up
to one third of ERA patients have markedly elevated Bac-
teroides content, while a second subset had similar overall
patterns of enteric bacteria to the controls, with the ex-
ception of lower Faecalibacterium. However, 7/17 of the
ERA group with normal Bacteroides content, compared to
0/8 of the group with elevated Bacteroides content, carried
increased frequencies of A. muciniphila. First described in
2004, it was originally isolated based upon its capacity to
thrive on intestinal mucin, suggesting that high quantities
could potentially lead to a defect in the intestinal wall bar-
rier function [43]. Although a European study indicated
that A. muciniphila typically comprises 1 to 3% of the in-
testinal microbiota [44], it is evidently less common in the
United States, or at least in our patient population, and
there may be regional differences in the overall microbiota
that could result in patients in this region being more sus-
ceptible to a pro-inflammatory effect of this bacterium.
This is the first study suggesting a potential role in in-
flammatory disease in humans, although a recent study of
mice infected with Salmonella demonstrated increased
histologic inflammatory scores and mRNA levels of
Figure 5 Divergent relationships between F. prausnitzii IgA levels and fecal F. prausnitzii content, between patients and controls.
Enthesitis-related arthritis (ERA) subjects are depicted in blue (broken line); controls are red (solid line).
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niphila [45].
Finally, elevated Bifidobacterium, mostly B. adolescentis,
was also identified among ERA patients. There are mixed
data with respect to this genus in the context of IBD, with
prior studies both showing elevated [31] as well as de-
creased presence [46]. Elevated bifidobacterium was also
seen in the study of AS patients [8]. Thus, overall, ERA
patients displayed a microbiota profile similar to that pub-
lished for IBD patients with respect to lower levels of
F. prausnitzii and possibly of Clostridium clostridioforme,
as well as alterations in B. adolescentis. Our findings are
also consistent with those reported in AS patients, despite
substantial differences in age and disease duration in the
current study compared to the previous [8].
IgA functions in part to protect the host against com-
mensal organisms [47,48]. It also has a regulatory role,
with downstream responses to IgA binding dependent
upon a variety of factors, including signaling events
through the IgA receptor and the location of the den-
dritic antigen presenting cells [49,50]. Thus, the inter-
pretation of discordant correlations between IgA and
16S levels between patients and controls is clouded by
the multiple functions of IgA. In the case of B. fragilis,
the relationship between the IgA and the sequence data
may represent invasion of the gut wall by the bacterium,triggering systemic immune responses. Alternatively, in
light of its potential regulatory role, the inverse relation-
ship between IgA against F. prausnitzii and the sequence
data may represent a failure of the system to generate a
regulatory T cell response normally thought to be in-
duced by this species [33]. Studies of T cell function are
required to evaluate these possibilities.
This study has several limitations. The patient numbers
are limited, and they included subjects with newly diag-
nosed as well as treated arthritis. However, a study of IBD
patients showed that while antibiotics and aminosalicy-
lates had important effects on the microbiota, immuno-
suppressive therapies appeared to have less of an impact
[51]. Exclusion of patients with IBD did not impact the
trends shown herein, although the association between
F. prausntzii levels and antibodies among ERA patients
was less robust (Additional file 1: Tables S4, S5).
An additional limitation is that information on the diet
of these subjects was unavailable on most of the pa-
tients. However, body mass index data were not pre-
dictive of the levels of any of the bacteria identified in
this study (Additional file 1: Table S1). Furthermore, al-
though the controls did have higher BMI compared to the
patients (Table 1), at the phylum level, the Firmicutes:
Bacteroidetes ratio was similar (2.97, 0.26 to 30 in ERA
patients compared to 3.46, 1.0 to 26 in controls, P = 0.199,
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verse relationship between body mass index and the
Firmicutes/Bacteroidetes ratio among the group as a whole
(r = −0.140, P = 0.401), the opposite direction that would
be expected if weight were the driving factor [52]. Finally,
there was no external validation of the differences in bac-
terial content observed in this study, nor was there objec-
tive measurement of intestinal inflammation (for example,
fecal calprotectin.) This is, nevertheless, the first compre-
hensive evaluation of the microbiota in pediatric or adult
SpA, confirming a potential role for insufficient protective
F. prausnitzii in the pathogenesis of ERA and introducing
potential novel bacteria as associative agents in ERA.
These findings suggest altering the gut microbiota may be
beneficial in children with ERA. Future directions will ex-
tend these findings in larger cohorts and also identify the
nature of the adaptive (antibody and T cell reactivity) im-
munologic response against these enteric commensal
organisms.
Conclusions
Our studies provide further evidence of a pathogenetic
link between IBD and SpA by showing a similar decrease
in fecal F. prausnitzii content in ERA patients as had pre-
viously been reported in subjects with IBD. In addition,
we introduce two organisms, Bacteroides genus and A.
muciniphila, as potential associative agents in subsets of
children with ERA. Finally, our data suggest that alter-
ations to IgA reactivities against commensal organisms
may play a role in ERA.
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